Similar articles

• Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

  Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group. Schrader J, et al. Stroke. 2005 Jun;36(6):1218-26. doi: 10.1161/01.STR.0000166048.35740.a9. Epub 2005 May 5. Stroke. 2005. PMID: 15879332 Clinical Trial.
• MOSES: superiority or noninferiority?

  Owen A. Owen A. Stroke. 2006 Feb;37(2):337; author reply 338. doi: 10.1161/01.STR.0000199615.57335.87. Epub 2006 Jan 5. Stroke. 2006. PMID: 16397180 Clinical Trial. No abstract available.
• [COPE trial].

  Umemoto S, Kamiya A, Matsuzaki M, Ogihara T. Umemoto S, et al. Nihon Rinsho. 2006 Aug;64 Suppl 6:470-4. Nihon Rinsho. 2006. PMID: 16981580 Review. Japanese. No abstract available.
• Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.

  Fournier A, Oprisiu-Fournier R, Serot JM, Godefroy O, Achard JM, Faure S, Mazouz H, Temmar M, Albu A, Bordet R, Hanon O, Gueyffier F, Wang J, Black S, Sato N. Fournier A, et al. Expert Rev Neurother. 2009 Sep;9(9):1413-31. doi: 10.1586/ern.09.89. Expert Rev Neurother. 2009. PMID: 19769454 Review.
• Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.

  Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K; OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group. Ogawa H, et al. Am J Med. 2012 Oct;125(10):981-90. doi: 10.1016/j.amjmed.2011.12.010. Epub 2012 Apr 14. Am J Med. 2012. PMID: 22503610 Clinical Trial.